Participants in the study will take the medication in the form of a capsule, which is taken by mouth once a day. The study will monitor the response to the treatment over a period of time to see how well it works in managing the conditions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to gather information on how the medication affects the body and its potential side effects.

By participating in this study, researchers hope to better understand the effectiveness of gandotinib in treating myeloproliferative neoplasms and to explore its potential as a treatment option for patients with these conditions. The study will help determine if this medication can improve the quality of life for those affected by these blood cancers.

The purpose of the study is to determine if low-dose DOACs are more effective than low-dose Aspirin in preventing blood clots in high-risk patients with these blood disorders. Participants in the study will be randomly assigned to receive either Apixaban, Rivaroxaban, or Aspirin. The study will monitor the time it takes for any blood clotting events to occur, as well as any significant bleeding events. The study will also look at other health outcomes, such as overall survival and quality of life, over a period of 24 months.

Throughout the study, participants will take their assigned medication orally, and their health will be closely monitored by the research team. The study will help to better understand which medication is more effective in preventing complications related to blood clots in patients with these specific blood disorders. The findings could lead to improved treatment options for individuals with these conditions.

The purpose of the study is to evaluate how safe and effective Ruxolitinib is compared to other treatments for patients with high-risk forms of these blood disorders. Participants in the study will receive either Ruxolitinib or the best available therapy, which may include other medications or treatments that are commonly used for these conditions. The study will last for a period of up to 145 days, during which participants will be monitored to assess their response to the treatment and any side effects they may experience.

Throughout the study, researchers will look at various outcomes, such as the rate of complete responses in blood cell counts and the reduction of symptoms related to the disorders. The study aims to provide valuable information on the potential benefits and risks of using Ruxolitinib for treating high-risk Polycythemia Vera and Essential Thrombocythemia, helping to improve future treatment options for these conditions.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

Participants in the study will receive both medications and will be monitored for any side effects or adverse reactions. The study will also look at how well the treatment works in controlling the disease by measuring various health indicators at different times throughout the study. These indicators include the levels of red blood cells, white blood cells, and platelets, as well as any symptoms related to the disease.

The trial aims to provide valuable information on the safety and effectiveness of using Peginterferon Alfa-2a and Ruxolitinib together in treating newly diagnosed patients with Polycythemia Vera. Participants will be closely monitored by healthcare professionals to ensure their well-being throughout the study period.

The purpose of the study is to determine which treatment is most effective at preventing serious complications in patients with high-risk Polycythemia Vera. The study will monitor patients for major blood clots, severe bleeding, disease progression to other blood disorders such as Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Post-PV Myelofibrosis, and overall survival.

Patients will be randomly assigned to receive either ruxolitinib tablets taken by mouth, or one of two comparison treatments: hydroxycarbamide capsules taken by mouth, or peginterferon alfa-2a given as an injection under the skin. The treatment and monitoring period will continue for up to 96 months, during which patients will have regular check-ups to assess their response to treatment and monitor for any side effects.

The purpose of the study is to determine which treatment is more effective and safer for patients with high-risk Polycythemia Vera. Participants in the study will receive either Givinostat or Hydroxyurea for a period of 48 weeks. During this time, doctors will monitor the patients to see how well the treatments work in controlling the disease and to check for any side effects. The study will also involve regular check-ups and tests to ensure the safety and well-being of the participants.

Throughout the study, the goal is to see if patients can maintain a healthy level of red blood cells without needing additional procedures like phlebotomy, which is a process to remove blood from the body. The study will also look at other factors such as white blood cell counts, platelet levels, and spleen size, which can be measured using imaging techniques like MRI or CT scans. The results will help determine the best treatment option for managing high-risk Polycythemia Vera.

The purpose of the study is to evaluate how safe and effective Rusfertide is in helping patients with Polycythemia Vera maintain control over their hematocrit levels, which is the proportion of red blood cells in the blood. Participants in the study will receive either Rusfertide or a placebo, which looks like the treatment but does not contain the active substance. The study will last for a period of time, during which participants will receive regular injections and have their blood monitored to see how well the treatment is working.

Throughout the study, the main goal is to see if Rusfertide can reduce the need for phlebotomies, which are procedures to remove blood from the body to lower red blood cell levels. The study will also look at other factors, such as changes in fatigue levels and overall well-being. This research aims to provide more information about the potential benefits of Rusfertide for people living with Polycythemia Vera.

The purpose of the study is to evaluate the safety and tolerability of bomedemstat. Participants in this study have previously been involved in a bomedemstat clinical trial and have been receiving the medication for at least six months. The study will continue to monitor these participants to ensure the treatment remains safe and to observe any potential side effects. Participants will take the medication at home and will be required to swallow the capsules as directed.

Throughout the study, researchers will keep track of any adverse events, which are unwanted effects that may occur during treatment. They will also monitor whether participants need to stop the treatment due to these effects. For those with essential thrombocythemia or polycythemia vera, the study will look at how long the treatment continues to work effectively. Additionally, the study will observe if there is any progression to more serious conditions like myelodysplastic syndrome or acute myeloid leukemia. The study aims to provide valuable information on the long-term use of bomedemstat for these conditions.

The purpose of the study is to see if sapablursen can reduce the number of times patients need phlebotomy over a specific period. Participants in the study will receive the treatment and be monitored for its effects on their condition. The study will last for a total of 37 weeks, with a focus on the last 20 weeks to assess the treatment’s effectiveness. During this time, researchers will also look at how the treatment affects symptoms and overall health.

Throughout the study, various health checks will be conducted, including blood tests and heart monitoring, to ensure the safety and well-being of participants. The study aims to provide valuable information on whether sapablursen can help manage Polycythemia Vera more effectively, potentially reducing the need for frequent phlebotomy and improving the quality of life for those affected by this condition.

Participants in the study will begin their regular treatment with hydroxyurea, and researchers will monitor them over a period of up to 15 months. The study will use advanced techniques, including artificial intelligence, to identify patients who might be resistant to hydroxyurea before they start treatment. This will help in understanding which patients are more likely to benefit from the medication and who might need alternative treatments.

Throughout the study, researchers will observe how many patients develop resistance or intolerance to hydroxyurea within the first 6 to 9 months and over the entire 15-month period. They will also look at the reasons why some patients might need to switch to different therapies and the timing of these changes. This information will be valuable in improving treatment strategies for polycythemia vera in the future.

The purpose of the study is to understand how safe and tolerable SLN124 is for patients with Polycythemia Vera and to see how it affects the need for phlebotomies, which are procedures to remove blood from the body. The study will be conducted in two phases. In the first phase, patients will receive different doses of SLN124 to assess its safety and how well it is tolerated. In the second phase, the study will compare the effects of SLN124 with a placebo to see if it helps maintain normal levels of hematocrit, which is the proportion of red blood cells in the blood, without needing phlebotomies.

Participants in the study will receive injections of SLN124 or a placebo and will be monitored over several weeks. The study aims to see if SLN124 can help manage Polycythemia Vera by reducing the need for frequent blood removal procedures and maintaining healthy blood levels. The trial will also look at any side effects and how the treatment affects the overall quality of life for the participants.